DK1497308T3 - Fremgangsmåde til fremstilling af krystaller af steroider, krystaller opnået ved hjælp heraf og anvendelse heraf i farmaceutiske formuleringer - Google Patents

Fremgangsmåde til fremstilling af krystaller af steroider, krystaller opnået ved hjælp heraf og anvendelse heraf i farmaceutiske formuleringer

Info

Publication number
DK1497308T3
DK1497308T3 DK03747107T DK03747107T DK1497308T3 DK 1497308 T3 DK1497308 T3 DK 1497308T3 DK 03747107 T DK03747107 T DK 03747107T DK 03747107 T DK03747107 T DK 03747107T DK 1497308 T3 DK1497308 T3 DK 1497308T3
Authority
DK
Denmark
Prior art keywords
crystals
steroids
preparation
mum
pharmaceutical formulations
Prior art date
Application number
DK03747107T
Other languages
English (en)
Inventor
Detlef Grawe
Hagen Gerecke
Peter Hoesel
Annette Eichardt
Sabine Gliesing
Uwe Mueller
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK1497308T3 publication Critical patent/DK1497308T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0085—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK03747107T 2002-04-23 2003-04-22 Fremgangsmåde til fremstilling af krystaller af steroider, krystaller opnået ved hjælp heraf og anvendelse heraf i farmaceutiske formuleringer DK1497308T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10218107A DE10218107A1 (de) 2002-04-23 2002-04-23 Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
PCT/EP2003/004154 WO2003091272A1 (de) 2002-04-23 2003-04-22 Verfahren zum herstellen von kristallen von steroiden, danach erhältliche kristalle und deren verwendung in pharmazeutischen formulierungen

Publications (1)

Publication Number Publication Date
DK1497308T3 true DK1497308T3 (da) 2007-01-29

Family

ID=29264787

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03747107T DK1497308T3 (da) 2002-04-23 2003-04-22 Fremgangsmåde til fremstilling af krystaller af steroider, krystaller opnået ved hjælp heraf og anvendelse heraf i farmaceutiske formuleringer

Country Status (20)

Country Link
US (1) US7148212B2 (da)
EP (1) EP1497308B1 (da)
JP (1) JP4490116B2 (da)
KR (1) KR20040106380A (da)
CN (1) CN1646555A (da)
AT (1) ATE340186T1 (da)
AU (1) AU2003232491A1 (da)
BR (1) BR0309357A (da)
CA (1) CA2480004C (da)
DE (2) DE10218107A1 (da)
DK (1) DK1497308T3 (da)
ES (1) ES2274258T3 (da)
IL (1) IL163986A0 (da)
MX (1) MXPA04010467A (da)
NO (1) NO20045023L (da)
PL (1) PL371340A1 (da)
PT (1) PT1497308E (da)
RU (1) RU2315056C2 (da)
WO (1) WO2003091272A1 (da)
ZA (1) ZA200409401B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
ES2327665T3 (es) * 2006-08-10 2009-11-02 JENAPHARM GMBH & CO. KG Forma medicamentosa peroral con dienogest y etinilestradiol para la contracepcion.
US20080038350A1 (en) * 2006-08-10 2008-02-14 Hagen Gerecke Low-dosage peroral medication for contraception containing crystalline dienogest and ethinyl estradiol
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
DE102010003711B4 (de) 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoffpartikel
RU2642244C2 (ru) * 2010-04-12 2018-01-24 Кларус Терапеутикс, Инк. Оральные фармацевтические композиции сложных эфиров тестостерона и способы лечения недостатка тестостерона с их использованием
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
EP3143001B1 (en) 2014-05-13 2018-07-18 Akzo Nobel Chemicals International B.V. Process to crystallize chelating agents
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
JP2021531348A (ja) 2018-07-20 2021-11-18 リポシン，インク． 肝臓病
US12570627B2 (en) 2020-05-15 2026-03-10 Shionogi & Co., Ltd. Pharmaceutical composition in which production of impurities is suppressed

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226389A (en) 1962-01-04 1965-12-28 Du Pont 11,11,12,12-tetracyano-naphtho-2,6-quinodimethan and its anion-radical salts
KR0132576B1 (ko) 1988-10-05 1998-04-17 로렌스 티. 웰츠 항-용매 내로의 침전을 통한 미분 고형물 결정 분말의 제조 방법
DE3917617A1 (de) 1989-05-31 1990-12-06 Boehringer Ingelheim Kg Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung
FR2668945B1 (fr) 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
ES2126977T3 (es) 1991-07-10 1999-04-01 Chiyoda Chem Eng Construct Co Procedimento para la produccion de aducto cristalino de bisfenol a y fenol.
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1995018018A1 (en) * 1993-12-27 1995-07-06 Nippon Soda Co. Ltd. 4-hydroxy-4'-isopropoxydiphenyl sulfone developer composition, wet pulverizing method, and dispersion
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
CN1183102C (zh) * 1998-12-25 2005-01-05 第一精密化学株式会社 泛酸钙的制备方法
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Also Published As

Publication number Publication date
DE10218107A1 (de) 2003-11-20
IL163986A0 (en) 2005-12-18
RU2004134324A (ru) 2006-02-10
PL371340A1 (en) 2005-06-13
CN1646555A (zh) 2005-07-27
MXPA04010467A (es) 2004-12-13
JP2005524698A (ja) 2005-08-18
EP1497308A1 (de) 2005-01-19
JP4490116B2 (ja) 2010-06-23
EP1497308B1 (de) 2006-09-20
US7148212B2 (en) 2006-12-12
NO20045023L (no) 2004-11-18
BR0309357A (pt) 2005-02-22
CA2480004A1 (en) 2003-11-06
RU2315056C2 (ru) 2008-01-20
ZA200409401B (en) 2006-02-22
KR20040106380A (ko) 2004-12-17
CA2480004C (en) 2007-11-13
AU2003232491A1 (en) 2003-11-10
US20030216360A1 (en) 2003-11-20
WO2003091272A1 (de) 2003-11-06
ATE340186T1 (de) 2006-10-15
DE50305122D1 (de) 2006-11-02
PT1497308E (pt) 2007-01-31
ES2274258T3 (es) 2007-05-16

Similar Documents

Publication Publication Date Title
NO20045073L (no) Fremgangsmate for fremstilling av krystaller, derved oppnaelige krystaller og deres anvendelse i farmasoytiske formuleringer
DK1497308T3 (da) Fremgangsmåde til fremstilling af krystaller af steroider, krystaller opnået ved hjælp heraf og anvendelse heraf i farmaceutiske formuleringer
DK0744941T3 (da) Fremgangsmåde til fremstilling af findelte farmaceutiske formuleringer
CA2412161A1 (en) Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones
HUT46847A (en) Process for producing retarde pharmaceutical compositions of oral application
ES2065499T3 (es) Alcohol sacarido cristalino que contiene compuesto farmaceutico particulado uniformemente disperso.
DK0937100T3 (da) En ny polymorfisk krystallinsk form af fluticasonpropionat, fremgangsmåder til fremstilling deraf og farmaceutiske præparater deraf
IL76457A0 (en) Tetralin derivatives,their preparation and pharmaceutical compositions containing them
NO20012514L (no) Fremgangsmate for fremstilling av partikler med en omdannet amorf og/eller meta-stabil krystallinsk region til krystallinsk tilstand
HUP0200284A3 (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders, process for their preparation and pharmaceutical compositions containing them
ES8505379A1 (es) Un metodo de fabricar 1, 4-dihidropiridina-3-carboxilatos
IL103005A0 (en) Process for producing pharmaceutical compositions
HUP0203429A3 (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone, process for their preparation and pharmaceutical compositions containing them
BG103060A (bg) 19- нор- холан стероиди като неврохимични инициатори на промяната в действието на хипоталамуса причовек
NO20045071L (no) Fremgangsmate for fremstilling av krystaller ut i fra aktive legemiddelvirkestoffer, krystaller oppnadd derav og deres anvendelse i farmasoytiske formuleringer
PT78030A (en) Process for the preparation of an ointment based in 17-alpha-propyloxi-11beta-hydroxi-4-pregnene-3,20-dione
WO2005044759A3 (en) Acetalization process for preparation of steroid compounds
FR2669533B1 (fr) Procede de preparation de formulations de spiramycine et formulations orales de spiramycine.
DK0946585T3 (da) Steroidforbindelser substitueret i stilling 11, fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf
JPS5259171A (en) Preparation of uracil derivatives
JPS51143656A (en) A process for preparing 7-dehydro cholesterol
AU1167097A (en) 18-methyl 16-methylene 19-nor pregnane derivatives as progestins, pharmaceutical compositions containing them and process for the preparation thereof
JPS5212987A (en) Manufacture of na glutamate
JPS5251373A (en) Preparaton of pyrmidine ucleosides
JPS537519A (en) Concentrating method for titanium component